CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system.

Our flagship product, Multikine®, is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer.

Multikine® is the first of a new class of cancer immunotherapy drugs called Immune SIMULATORs. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine® is multi-targeted; it is the only cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer.

Multikine® is a different kind of weapon in the fight against cancer; one that unleashes and empowers the body's own anti-tumor immune response.

Multikine® has been cleared in the U.S. and Canada for study in a global Phase III clinical trial in advanced primary (not yet treated) head and neck cancer patients.

CEL-SCI's other immunotherapy products (L.E.A.P.S.(TM) conjugates) are currently in various stages of pre-clinical development. These products have shown to protect treated animals from infection or disease by a number of viruses and parasitic agents against which they have been tested.  CEL-2000 has shown considerable promise as a therapeutic vaccine for rheumatoid arthritis.  The initial tests in animals showed that CEL-2000 is equivalent or possibly superior to Enbrel®, a leading treatment for people with rheumatoid arthritis, in slowing disease progression and lessening symptoms.  The potential of CEL-1000, another product candidate, to provide broad spectrum protection for individuals prior to an unanticipated exposure to unknown infectious agents make it particularly suitable for development as a bio-defense agent, or for use in protecting individuals at very high risk of unknown infections from occupational or environmental exposure.